Jci_page_head_homepage_01 Jci_page_head_homepage_02
Britta George, Rakesh Verma, Abdulsalam A. Soofi, Puneet Garg, Jidong Zhang, Tae-Ju Park, Laura Giardino, Larisa Ryzhova, Duncan B. Johnstone, Hetty Wong, Deepak Nihalani, David J. Salant, Steven K. Hanks, Tom Curran, Maria Pia Rastaldi, Lawrence B. Holzman
Published in Volume 122, Issue 2
J Clin Invest. 2012; 122(2):674–692 doi:10.1172/JCI60070
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Jci60070
Figure 14
Enhanced Cas and FAK phosphorylation in membranous nephropathy and minimal change disease.

(A) Representative images showing anti–p-Cas (green) and anti–p-FAK (green) antibody staining of frozen kidney sections from control subjects and from patients with focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), or minimal change disease (MCD). (B) Coimmunofluorescence study of frozen kidney sections of patients with minimal change disease with anti–p-Cas (green) or anti–p-FAK antibody (green) and the podocyte slit diaphragm marker synaptopodin (red). Higher-magnification images are shown below. Note that p-Cas and p-FAK almost completely colocalized with synaptopodin. Original magnification, ×400 (A and B, top); ×1,000 (B, bottom).